Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

FDA Accepts BLA Resubmission for Denileukin Diftitox in Relapsed/Refractory Cutaneous T-Cell Lymphoma

March 18th 2024

The FDA has accepted the resubmission of the BLA seeking the approval of denileukin diftitox-cxdl for relapsed/refractory cutaneous T-cell lymphoma.

Brentuximab Vedotin Plus Lenalidomide and Rituximab Generates OS Benefit in Previously Treated DLBCL

March 12th 2024

Brentuximab vedotin/lenalidomide/rituximab led to an OS improvement vs lenalidomide/rituximab/placebo in relapsed/refractory diffuse large B-cell lymphoma.

FDA Lifts Partial Clinical Hold on Trial Evaluating NX-2127 in R/R B-Cell Malignancies

March 11th 2024

The FDA has lifted a partial clinical hold on a phase 1 trial evaluating NX-2127 in relapsed/refractory B-cell malignancies

FDA Grants Accelerated Approval to Zanubrutinib Plus Obinutuzumab for Relapsed or Refractory Follicular Lymphoma

March 7th 2024

The FDA granted accelerated approval to zanubrutinib in combination with obinutuzumab for select patients with relapsed/refractory follicular lymphoma.

Dr Moustafa on the Evolving Use of Bispecific Antibodies in DLBCL

March 6th 2024

Muhamad Alhaj Moustafa, MD, MS, discusses the evolution of bispecific antibodies in diffuse large B-cell lymphoma.

Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL

February 24th 2024

Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.

Acalabrutinib/Axi-Cel Generates Preliminary Responses in Relapsed/Refractory B-Cell Lymphoma

February 23rd 2024

Early data seen with acalabrutinib plus axi-cel indicate the combination’s feasibility as bridging therapy in relapsed/refractory B-cell lymphoma.

CNS Remission Achieved With Brexu-Cel in Relapsed/Refractory B-ALL

February 22nd 2024

Brexu-cel showed efficacy in eliciting both CNS and systemic responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL

February 18th 2024

Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.

Dr Vose on Mitigating Epcoritamab-Associated CRS and Neurologic Toxicities in R/R DLBCL

January 30th 2024

Julie M. Vose, MD, MBA, discusses the mitigation of toxicities with epcoritamab in an optimization cohort of patients with relapsed/refractory DLBCL.

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL

January 9th 2024

BRL-201 had a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma.

Research Developments Provide Clarity and Raise Further Questions in Myeloma, Myelofibrosis, DLBCL, and MDS

January 5th 2024

Sikander Ailawadhi, MD, discusses characteristics of myelofibrosis that influence decisions between JAK inhibitors, highlights differences between bispecific antibodies to consider when managing diffuse large B-cell lymphoma, and more.

Dr Leslie on the Clinical Benefit of Axi-Cel in Elderly Patients With R/R LBCL

January 2nd 2024

Lori A. Leslie, MD, discusses the efficacy and safety of second-line axicabtagene ciloleucel in elderly patients with high-risk, relapsed/refractory large B-cell lymphoma.

FDA Approves Label Updates to Include New Data for Axi-Cel in LBCL, Zanubrutinib in CLL

December 22nd 2023

The FDA has approved label updates for zanubrutinib to include data from the ALPINE trial in relapsed/refractory chronic lymphocytic leukemia, and axicabtagene ciloleucel to include findings from the primary overall survival analysis of the ZUMA-7 trial in relapsed/refractory large B-cell lymphoma.

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023

Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.

DZD8586 Demonstrates Responses Across Dose Levels in B-Cell Non-Hodgkin Lymphoma

December 13th 2023

DZD8586 showcased antitumor activity and favorable safety with limited grade 3 or greater treatment-emergent adverse effects in patients with heavily pretreated B-cell non-Hodgkin lymphoma, according to preliminary findings from a pooled analysis of two ongoing phase 1 trials.

NX-2127 Elicits Responses With Manageable Safety in Heavily Pretreated B-cell Malignancies

December 12th 2023

NX-2127 showcased early efficacy in the form of responses with an acceptable toxicity profile in patients with relapsed or refractory B-cell malignancies, according to data from the ongoing phase 1 NX-2127-001 trial.

Dr Andorsky on Real-World Treatment Patterns With BTK Inhibitors in CLL/SLL

December 12th 2023

David J. Andorsky, MD, discusses recently observed patterns of care with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma in the community setting in the United States, and how social determinants of health may have affected these outcomes.

Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies

December 11th 2023

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma

December 11th 2023

Patients with relapsed/refractory follicular lymphoma experienced durable responses when treated with tisagenlecleucel (Kymriah) in the phase 2 ELARA study (NCT03568461), according to data presented at the 2023 ASH Annual Meeting.